Loading...
Loading...
India's semaglutide imports from NETHERLANDS total $81.3K across 11 shipments from 3 foreign suppliers. ABACUS MEDICINE A/S leads with $67.5K in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include ZYDUS LIFESCIENCES LIMITED. This corridor reflects India's pharmaceutical import demand for semaglutide โ a concentrated sourcing relationship with select suppliers from NETHERLANDS.

ABACUS MEDICINE A/S is the leading Semaglutide supplier from NETHERLANDS to India, with import value of $67.5K across 1 shipments. The top 5 suppliers โ ABACUS MEDICINE A/S, BMCLINICAL BV, QUANTIME WORLD INC โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | ABACUS MEDICINE A/S | $67.5K | 1 | 83.0% |
| 2 | BMCLINICAL BV | $7.1K | 9 | 8.8% |
| 3 | QUANTIME WORLD INC | $6.7K | 1 | 8.2% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | ZYDUS LIFESCIENCES LIMITED | $67.5K | 1 | 83.0% |
| 2 | DR.REDDY'S LABORATORIES LTD | $7.1K | 9 | 8.8% |
| 3 | WOCKHARDT LIMITED |
NETHERLANDS โ India trade corridor intelligence
As of April 2026, the Netherlands to India trade corridor for Semaglutide formulations is operating efficiently. Major ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are handling shipments without significant congestion. Freight rates have stabilized, and the exchange rate between the Indian Rupee (INR) and the Euro remains favorable for importers. No major disruptions have been reported in the supply chain, ensuring a steady flow of Semaglutide formulations from the Netherlands to India.
The Production-Linked Incentive (PLI) scheme has been a significant factor in India's push for self-reliance in pharmaceutical manufacturing. While this initiative aims to reduce dependency on imports, it has also impacted the import of finished formulations like Semaglutide. The government encourages domestic production through incentives, which may affect the volume of imports from countries like the Netherlands. Import substitution policies are being implemented to promote local manufacturing capabilities, potentially reducing the need for imports in the future.
| $6.7K |
| 1 |
| 8.2% |
India and the Netherlands share a robust trade relationship, with mutual recognition of Good Manufacturing Practices (GMP) facilitating smoother pharmaceutical trade. Ongoing Free Trade Agreement (FTA) negotiations aim to further enhance bilateral trade, including the pharmaceutical sector. Both countries are committed to streamlining approval processes and ensuring the quality and safety of pharmaceutical imports and exports. These efforts contribute to a favorable environment for the trade of Semaglutide formulations between the Netherlands and India.
The landed cost of importing Semaglutide formulations from the Netherlands to India includes several components:
These components collectively determine the per-unit landed cost of Semaglutide formulations imported from the Netherlands to India.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Semaglutide into India, the Central Drugs Standard Control Organization (CDSCO) mandates that both the importer and the product be registered. The importer must obtain an Import License from the Directorate General of Foreign Trade (DGFT), and the product requires CDSCO approval, typically involving the submission of Form CT-20/40/41. The registration process includes providing stability data (ICH Zone IV), a Certificate of Pharmaceutical Product (CoPP), and a No Objection Certificate (NOC) from the manufacturer. The timeline for import drug registration varies but generally takes several months, depending on the completeness of the application and regulatory review. For Semaglutide formulations under HS Code 30049099, specific requirements include demonstrating compliance with Indian Pharmacopoeia standards and providing detailed product dossiers.
Imported Semaglutide formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to ensure product efficacy and safety. Port inspections by customs drug inspectors are conducted to verify the authenticity and quality of the imported products. If a batch fails quality testing, it may be subject to rejection, re-exportation, or destruction, depending on the severity of the non-compliance.
Between 2024 and 2026, the CDSCO introduced stricter regulations for imported medicines, including mandatory import registration and licensing to prevent the sale of unapproved or illegal drugs in the Indian market. The Production-Linked Incentive (PLI) scheme, implemented to boost domestic manufacturing, has impacted the import of finished formulations, encouraging self-reliance and reducing dependency on imports. Bilateral agreements between India and the Netherlands have facilitated smoother trade relations, with mutual recognition of Good Manufacturing Practices (GMP) and streamlined approval processes for pharmaceutical imports.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 10%
India imports finished Semaglutide formulations primarily due to the unavailability of certain patented or branded formulations domestically. Specific dosage forms and strengths not produced locally necessitate imports to meet patient needs. The domestic capacity for manufacturing Semaglutide formulations is limited, leading to a reliance on imports to fulfill market demand. The market size for Semaglutide formulations in India is substantial, with a growing number of patients requiring treatment for diabetes and obesity.
The Basic Customs Duty (BCD) for Semaglutide formulations under HS Code 30049099 is 10%. The Social Welfare Surcharge (SWS) is 10% of the BCD, resulting in an additional 1% duty. Integrated Goods and Services Tax (IGST) is applicable, with rates varying based on the product classification. There are no exemptions or preferential rates for imports from the Netherlands. The total landed duty percentage combines these components, affecting the final cost of imported Semaglutide formulations.
India sources Semaglutide formulations from the Netherlands due to the availability of patented formulations and specialized dosage forms not produced domestically. Dutch manufacturers are known for high-quality standards and compliance with international regulatory requirements, ensuring product safety and efficacy. While other suppliers like China, Germany, and the United States also export Semaglutide formulations to India, the Netherlands maintains a competitive edge through consistent quality and reliable supply chains. The Netherlands holds a significant share in the Indian market for Semaglutide imports, reflecting its strong position as a supplier.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Semaglutide formulations from the Netherlands due to the availability of patented formulations and specialized dosage forms not produced domestically. Dutch manufacturers offer high-quality products that meet international standards, ensuring safety and efficacy. The Netherlands's strong regulatory compliance and reliable supply chains make it a preferred source for these formulations.
Compared to other origins like China, Germany, and the United States, the Netherlands offers competitive advantages in terms of product quality, regulatory compliance, and supply chain reliability. Dutch manufacturers adhere to stringent quality control measures, ensuring that Semaglutide formulations meet the required standards. While other countries may offer lower prices, the Netherlands's consistent quality and adherence to international regulations provide a unique advantage for Indian importers.
Indian importers face several supply chain risks when sourcing Semaglutide formulations from the Netherlands, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider diversifying their supplier base, closely monitoring currency exchange rates, staying updated on regulatory changes, and establishing contingency plans for potential shipping disruptions. Past shortages have been minimal, but proactive risk management is essential to ensure a steady supply.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Semaglutide suppliers from NETHERLANDS to India include ABACUS MEDICINE A/S, BMCLINICAL BV, QUANTIME WORLD INC. The leading supplier is ABACUS MEDICINE A/S with import value of $67.5K USD across 1 shipments. India imported Semaglutide worth $81.3K USD from NETHERLANDS in total across 11 shipments.
India imported Semaglutide worth $81.3K USD from NETHERLANDS across 11 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Semaglutide sourced from NETHERLANDS include ZYDUS LIFESCIENCES LIMITED, DR.REDDY'S LABORATORIES LTD, WOCKHARDT LIMITED. The largest buyer is ZYDUS LIFESCIENCES LIMITED with $67.5K in imports across 1 shipments.
The total value of Semaglutide imports from NETHERLANDS to India is $81.3K USD, across 11 shipments and 3 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
11 Verified Shipments
3 suppliers, 3 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists